Literature DB >> 14698252

Investigation of chromatographic conditions for the separation of cefuroxime axetil and its geometric isomer.

Ljiljana Zivanovic1, Ivana Ivanovic, Sote Vladimirov, Mira Zecevic.   

Abstract

The optimal chromatographic conditions for the separation of the syn- and anti-geometric isomers of cefuroxime axetil applying RP-HPLC and micellar liquid chromatography (MLC) methods were investigated. The possibility to separate diastereoisomers of syn- and anti-cefuroxime axetil was observed. Investigations were performed using three columns, two classical silicas and one with hybrid particle technology. Three aqueous-organic and one micellar mobile phases were used. The best results were achieved using micellar mobile phase. Optimization study was performed using different micellar mobile phases. MLC method is sensitive and applicable in purity and stability testing.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14698252     DOI: 10.1016/j.jchromb.2003.08.046

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  3 in total

1.  Application of vibrational spectroscopy supported by theoretical calculations in identification of amorphous and crystalline forms of cefuroxime axetil.

Authors:  Alicja Talaczyńska; Kornelia Lewandowska; Anna Jelińska; Piotr Garbacki; Agnieszka Podborska; Przemysław Zalewski; Irena Oszczapowicz; Adam Sikora; Maciej Kozak; Judyta Cielecka-Piontek
Journal:  ScientificWorldJournal       Date:  2015-01-11

2.  Development of nanoemulsion for efficient brain parenteral delivery of cefuroxime: designs, characterizations, and pharmacokinetics.

Authors:  Siti Norhawani Harun; Syafinaz Amin Nordin; Siti Salwa Abd Gani; Ahmad Fuad Shamsuddin; Mahiran Basri; Hamidon Bin Basri
Journal:  Int J Nanomedicine       Date:  2018-04-27

3.  Spectrophotometeric Determination of Cefuroxime Axetil from bulk and in its tablet dosage form.

Authors:  M V Shinde; S A Pishawikar; H N More
Journal:  Indian J Pharm Sci       Date:  2008 Mar-Apr       Impact factor: 0.975

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.